Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Type 2 Diabetes with Gut Dysbiosis
NCT03758144Unknown
- Sponsor
- Zagazig University
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in type 2 diabetes mellitus (T2DM), sponsored by Zagazig University. Primary endpoint: change in glycemic control at 3 months. Status: unknown.
02
Drugs
rifaximin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03758144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758144.